ID   ZDHC5_HUMAN             Reviewed;         715 AA.
AC   Q9C0B5; Q2TGF0; Q6ZMF0; Q8TAK8; Q9H923; Q9UFI7;
DT   01-FEB-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2003, sequence version 2.
DT   28-JUN-2023, entry version 175.
DE   RecName: Full=Palmitoyltransferase ZDHHC5;
DE            EC=2.3.1.225 {ECO:0000269|PubMed:29185452, ECO:0000269|PubMed:31402609, ECO:0000269|PubMed:31649195};
DE   AltName: Full=Zinc finger DHHC domain-containing protein 5;
DE            Short=DHHC-5;
DE   AltName: Full=Zinc finger protein 375;
GN   Name=ZDHHC5; Synonyms=KIAA1748, ZNF375;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Huang C.-H., Chen Y., Ye T.;
RT   "A superfamily of membrane-associated DHHC type zinc finger proteins.";
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 508-715 (ISOFORMS 1/2).
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-432, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-621, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-621, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-345; THR-348;
RP   SER-380; SER-409; SER-432; THR-436; SER-554; SER-621; THR-659 AND SER-694,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-432; THR-436 AND SER-621, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380; SER-432; SER-621;
RP   SER-684 AND SER-694, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=21820437; DOI=10.1016/j.febslet.2011.07.028;
RA   Kokkola T., Kruse C., Roy-Pogodzik E.M., Pekkinen J., Bauch C., Honck H.H.,
RA   Hennemann H., Kreienkamp H.J.;
RT   "Somatostatin receptor 5 is palmitoylated by the interacting ZDHHC5
RT   palmitoyltransferase.";
RL   FEBS Lett. 585:2665-2670(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-621, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-247; SER-299; SER-380;
RP   SER-398; SER-406; SER-409; THR-411; SER-415; SER-425; SER-432; THR-436;
RP   SER-529; SER-554; SER-621; SER-684 AND SER-694, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380 AND SER-554, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-617, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [20]
RP   FUNCTION, INTERACTION WITH DLG4, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   TYR-533, MUTAGENESIS OF TYR-533, AND AUTOPALMITOYLATION.
RX   PubMed=26334723; DOI=10.1038/ncomms9200;
RA   Brigidi G.S., Santyr B., Shimell J., Jovellar B., Bamji S.X.;
RT   "Activity-regulated trafficking of the palmitoyl-acyl transferase DHHC5.";
RL   Nat. Commun. 6:8200-8200(2015).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=29185452; DOI=10.1038/s41598-017-16457-4;
RA   Badawy S.M.M., Okada T., Kajimoto T., Ijuin T., Nakamura S.I.;
RT   "DHHC5-mediated palmitoylation of S1P receptor subtype 1 determines G-
RT   protein coupling.";
RL   Sci. Rep. 7:16552-16552(2017).
RN   [22]
RP   FUNCTION, SUBCELLULAR LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=31402609; DOI=10.15252/embr.201847472;
RA   Woodley K.T., Collins M.O.;
RT   "S-acylated Golga7b stabilises DHHC5 at the plasma membrane to regulate
RT   cell adhesion.";
RL   EMBO Rep. 20:e47472-e47472(2019).
RN   [23]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=31649195; DOI=10.1126/science.aau6391;
RA   Lu Y., Zheng Y., Coyaud E., Zhang C., Selvabaskaran A., Yu Y., Xu Z.,
RA   Weng X., Chen J.S., Meng Y., Warner N., Cheng X., Liu Y., Yao B., Hu H.,
RA   Xia Z., Muise A.M., Klip A., Brumell J.H., Girardin S.E., Ying S.,
RA   Fairn G.D., Raught B., Sun Q., Neculai D.;
RT   "Palmitoylation of NOD1 and NOD2 is required for bacterial sensing.";
RL   Science 366:460-467(2019).
RN   [24]
RP   FUNCTION, PHOSPHORYLATION AT TYR-91, MUTAGENESIS OF TYR-91, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=32958780; DOI=10.1038/s41467-020-18565-8;
RA   Hao J.W., Wang J., Guo H., Zhao Y.Y., Sun H.H., Li Y.F., Lai X.Y., Zhao N.,
RA   Wang X., Xie C., Hong L., Huang X., Wang H.R., Li C.B., Liang B., Chen S.,
RA   Zhao T.J.;
RT   "CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated
RT   endocytosis.";
RL   Nat. Commun. 11:4765-4765(2020).
RN   [25]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=34293401; DOI=10.1016/j.jlr.2021.100097;
RA   Dixon C.L., Fairn G.D.;
RT   "S-palmitoylation of NOD2 controls its localization to the plasma
RT   membrane.";
RL   J. Lipid Res. 62:100097-100097(2021).
CC   -!- FUNCTION: Palmitoyltransferase that catalyzes the addition of palmitate
CC       onto various protein substrates such as CTNND2, CD36, NOD1, NOD2, STAT3
CC       and S1PR1 thus plays a role in various biological processes including
CC       cell adhesion, fatty acid uptake, bacterial sensing or cardiac
CC       functions (PubMed:21820437, PubMed:29185452, PubMed:31402609,
CC       PubMed:31649195, PubMed:34293401). Plays an important role in the
CC       regulation of synapse efficacy by mediating palmitoylation of delta-
CC       catenin/CTNND2, thereby increasing synaptic delivery and surface
CC       stabilization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic
CC       acid receptors (AMPARs). Under basal conditions, remains at the
CC       synaptic membrane through FYN-mediated phosphorylation that prevents
CC       association with endocytic proteins (PubMed:26334723). Neuronal
CC       activity enhances the internalization and trafficking of DHHC5 from
CC       spines to dendritic shafts where it palmitoylates delta-catenin/CTNND2
CC       (PubMed:26334723). Regulates cell adhesion at the plasma membrane by
CC       palmitoylating GOLGA7B and DSG2 (PubMed:31402609). Plays a role in
CC       innate immune response by mediating the palmitoylation of NOD1 and NOD2
CC       and their proper recruitment to the bacterial entry site and phagosomes
CC       (PubMed:31649195, PubMed:34293401). Participates also in fatty acid
CC       uptake by palmitoylating CD36 and thereby targeting it to the plasma
CC       membrane. Upon binding of fatty acids to CD36, gets phosphorylated by
CC       LYN leading to inactivation and subsequent CD36 caveolar endocytosis
CC       (PubMed:32958780). Controls oligodendrocyte development by catalyzing
CC       STAT3 palmitoylation (By similarity). {ECO:0000250|UniProtKB:Q8VDZ4,
CC       ECO:0000269|PubMed:21820437, ECO:0000269|PubMed:26334723,
CC       ECO:0000269|PubMed:29185452, ECO:0000269|PubMed:31402609,
CC       ECO:0000269|PubMed:31649195, ECO:0000269|PubMed:32958780,
CC       ECO:0000269|PubMed:34293401}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hexadecanoyl-CoA + L-cysteinyl-[protein] = CoA + S-
CC         hexadecanoyl-L-cysteinyl-[protein]; Xref=Rhea:RHEA:36683, Rhea:RHEA-
CC         COMP:10131, Rhea:RHEA-COMP:11032, ChEBI:CHEBI:29950,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57379, ChEBI:CHEBI:74151;
CC         EC=2.3.1.225; Evidence={ECO:0000269|PubMed:29185452,
CC         ECO:0000269|PubMed:31402609, ECO:0000269|PubMed:31649195,
CC         ECO:0000269|PubMed:34293401};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36684;
CC         Evidence={ECO:0000269|PubMed:29185452, ECO:0000269|PubMed:31402609,
CC         ECO:0000269|PubMed:31649195, ECO:0000269|PubMed:34293401};
CC   -!- INTERACTION:
CC       Q9C0B5; Q2TAP0: GOLGA7B; NbExp=3; IntAct=EBI-2799626, EBI-13310443;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26334723,
CC       ECO:0000269|PubMed:29185452, ECO:0000269|PubMed:31402609,
CC       ECO:0000269|PubMed:32958780}; Multi-pass membrane protein
CC       {ECO:0000255}. Synapse {ECO:0000269|PubMed:26334723}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9C0B5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9C0B5-2; Sequence=VSP_006935;
CC   -!- DOMAIN: The DHHC domain is required for palmitoyltransferase activity.
CC       {ECO:0000250|UniProtKB:Q8IUH5}.
CC   -!- PTM: Phosphorylation regulates association with endocytic proteins and
CC       its subcellular localization (PubMed:26334723). Phosphorylation by LYN
CC       during fatty acid uptake leads to inactivation of the activity
CC       (PubMed:32958780). {ECO:0000269|PubMed:26334723,
CC       ECO:0000269|PubMed:32958780}.
CC   -!- PTM: Autopalmitoylated (PubMed:26334723). Palmitoylation of the C-
CC       terminal tail regulates stimulation-dependent plasma membrane motility
CC       (By similarity). {ECO:0000250|UniProtKB:Q2THW7,
CC       ECO:0000269|PubMed:26334723}.
CC   -!- SIMILARITY: Belongs to the DHHC palmitoyltransferase family.
CC       ERF2/ZDHHC9 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB21839.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAD18778.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB051535; BAB21839.1; ALT_INIT; mRNA.
DR   EMBL; AY894889; AAX73368.1; -; mRNA.
DR   EMBL; AK023130; BAB14420.1; -; mRNA.
DR   EMBL; AK172807; BAD18778.1; ALT_INIT; mRNA.
DR   EMBL; CH471076; EAW73771.1; -; Genomic_DNA.
DR   EMBL; BC026967; AAH26967.1; -; mRNA.
DR   EMBL; AL117662; CAB56033.1; -; mRNA.
DR   CCDS; CCDS7965.1; -. [Q9C0B5-1]
DR   PIR; T17343; T17343.
DR   RefSeq; NP_056272.2; NM_015457.2. [Q9C0B5-1]
DR   RefSeq; XP_011543201.1; XM_011544899.1. [Q9C0B5-1]
DR   RefSeq; XP_011543202.1; XM_011544900.1. [Q9C0B5-1]
DR   RefSeq; XP_011543203.1; XM_011544901.1. [Q9C0B5-1]
DR   AlphaFoldDB; Q9C0B5; -.
DR   BioGRID; 117422; 110.
DR   IntAct; Q9C0B5; 514.
DR   MINT; Q9C0B5; -.
DR   STRING; 9606.ENSP00000287169; -.
DR   GlyGen; Q9C0B5; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9C0B5; -.
DR   PhosphoSitePlus; Q9C0B5; -.
DR   SwissPalm; Q9C0B5; -.
DR   BioMuta; ZDHHC5; -.
DR   DMDM; 28202103; -.
DR   EPD; Q9C0B5; -.
DR   jPOST; Q9C0B5; -.
DR   MassIVE; Q9C0B5; -.
DR   MaxQB; Q9C0B5; -.
DR   PaxDb; Q9C0B5; -.
DR   PeptideAtlas; Q9C0B5; -.
DR   ProteomicsDB; 79989; -. [Q9C0B5-1]
DR   ProteomicsDB; 79990; -. [Q9C0B5-2]
DR   Antibodypedia; 3027; 123 antibodies from 22 providers.
DR   DNASU; 25921; -.
DR   Ensembl; ENST00000287169.8; ENSP00000287169.3; ENSG00000156599.11. [Q9C0B5-1]
DR   Ensembl; ENST00000527985.5; ENSP00000432202.1; ENSG00000156599.11. [Q9C0B5-2]
DR   GeneID; 25921; -.
DR   KEGG; hsa:25921; -.
DR   MANE-Select; ENST00000287169.8; ENSP00000287169.3; NM_015457.3; NP_056272.2.
DR   UCSC; uc001nkx.2; human. [Q9C0B5-1]
DR   AGR; HGNC:18472; -.
DR   CTD; 25921; -.
DR   DisGeNET; 25921; -.
DR   GeneCards; ZDHHC5; -.
DR   HGNC; HGNC:18472; ZDHHC5.
DR   HPA; ENSG00000156599; Low tissue specificity.
DR   MIM; 614586; gene.
DR   neXtProt; NX_Q9C0B5; -.
DR   OpenTargets; ENSG00000156599; -.
DR   PharmGKB; PA38338; -.
DR   VEuPathDB; HostDB:ENSG00000156599; -.
DR   eggNOG; KOG1311; Eukaryota.
DR   GeneTree; ENSGT00940000156001; -.
DR   HOGENOM; CLU_013779_0_0_1; -.
DR   InParanoid; Q9C0B5; -.
DR   OMA; LAPRYMG; -.
DR   OrthoDB; 5480099at2759; -.
DR   PhylomeDB; Q9C0B5; -.
DR   TreeFam; TF354263; -.
DR   BRENDA; 2.3.1.225; 2681.
DR   PathwayCommons; Q9C0B5; -.
DR   Reactome; R-HSA-9694548; Maturation of spike protein.
DR   SignaLink; Q9C0B5; -.
DR   SIGNOR; Q9C0B5; -.
DR   BioGRID-ORCS; 25921; 23 hits in 1186 CRISPR screens.
DR   ChiTaRS; ZDHHC5; human.
DR   GenomeRNAi; 25921; -.
DR   Pharos; Q9C0B5; Tbio.
DR   PRO; PR:Q9C0B5; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9C0B5; protein.
DR   Bgee; ENSG00000156599; Expressed in esophagus squamous epithelium and 183 other tissues.
DR   ExpressionAtlas; Q9C0B5; baseline and differential.
DR   Genevisible; Q9C0B5; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0045335; C:phagocytic vesicle; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0099091; C:postsynaptic specialization, intracellular component; IEA:Ensembl.
DR   GO; GO:0016409; F:palmitoyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0019706; F:protein-cysteine S-palmitoyltransferase activity; IDA:FlyBase.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006869; P:lipid transport; IEA:UniProtKB-KW.
DR   GO; GO:0062208; P:positive regulation of pattern recognition receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:1905171; P:positive regulation of protein localization to phagocytic vesicle; IEA:Ensembl.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0018345; P:protein palmitoylation; IDA:UniProtKB.
DR   GO; GO:0099072; P:regulation of postsynaptic membrane neurotransmitter receptor levels; IEA:Ensembl.
DR   InterPro; IPR001594; Palmitoyltrfase_DHHC.
DR   PANTHER; PTHR12349; ANKYRIN REPEAT AND LEM DOMAIN-CONTAINING PROTEIN 2; 1.
DR   PANTHER; PTHR12349:SF3; PALMITOYLTRANSFERASE ZDHHC5; 1.
DR   Pfam; PF01529; DHHC; 1.
DR   PROSITE; PS50216; DHHC; 1.
PE   1: Evidence at protein level;
KW   Acyltransferase; Alternative splicing; Cell membrane; Immunity;
KW   Innate immunity; Lipid transport; Lipoprotein; Membrane; Methylation;
KW   Palmitate; Phosphoprotein; Reference proteome; Synapse; Transferase;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..715
FT                   /note="Palmitoyltransferase ZDHHC5"
FT                   /id="PRO_0000212868"
FT   TOPO_DOM        1..13
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        14..34
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        35..38
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        39..59
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        60..148
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        149..169
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        170..191
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        192..212
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        213..715
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          104..154
FT                   /note="DHHC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00067"
FT   REGION          289..715
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        331..345
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        354..405
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        416..482
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        570..593
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        632..646
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        662..687
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        134
FT                   /note="S-palmitoyl cysteine intermediate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDZ4"
FT   MOD_RES         91
FT                   /note="Phosphotyrosine; by LYN"
FT                   /evidence="ECO:0000269|PubMed:32958780"
FT   MOD_RES         247
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         294
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDZ4"
FT   MOD_RES         296
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         299
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         303
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDZ4"
FT   MOD_RES         345
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         348
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         350
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDZ4"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         406
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         411
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         415
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         425
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         429
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDZ4"
FT   MOD_RES         432
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         436
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         529
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         533
FT                   /note="Phosphotyrosine; by FYN"
FT                   /evidence="ECO:0000269|PubMed:26334723"
FT   MOD_RES         554
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         617
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         621
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         659
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         684
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         694
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         697
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDZ4"
FT   VAR_SEQ         1..53
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_006935"
FT   MUTAGEN         91
FT                   /note="Y->E: More than 50% loss of activity."
FT                   /evidence="ECO:0000269|PubMed:32958780"
FT   MUTAGEN         533
FT                   /note="Y->E: More than 50% loss of FYN-mediated
FT                   phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:26334723"
FT   CONFLICT        508..509
FT                   /note="QQ -> TR (in Ref. 6; CAB56033)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   715 AA;  77545 MW;  9E4FB0C9AC8EFE28 CRC64;
     MPAESGKRFK PSKYVPVSAA AIFLVGATTL FFAFTCPGLS LYVSPAVPIY NAIMFLFVLA
     NFSMATFMDP GIFPRAEEDE DKEDDFRAPL YKTVEIKGIQ VRMKWCATCR FYRPPRCSHC
     SVCDNCVEEF DHHCPWVNNC IGRRNYRYFF LFLLSLTAHI MGVFGFGLLY VLYHIEELSG
     VRTAVTMAVM CVAGLFFIPV AGLTGFHVVL VARGRTTNEQ VTGKFRGGVN PFTNGCCNNV
     SRVLCSSPAP RYLGRPKKEK TIVIRPPFLR PEVSDGQITV KIMDNGIQGE LRRTKSKGSL
     EITESQSADA EPPPPPKPDL SRYTGLRTHL GLATNEDSSL LAKDSPPTPT MYKYRPGYSS
     SSTSAAMPHS SSAKLSRGDS LKEPTSIAES SRHPSYRSEP SLEPESFRSP TFGKSFHFDP
     LSSGSRSSSL KSAQGTGFEL GQLQSIRSEG TTSTSYKSLA NQTRNGSLSY DSLLTPSDSP
     DFESVQAGPE PDPPLGYTSP FLSARLAQQR EAERHPRLVP TGPTHREPSP VRYDNLSRHI
     VASLQEREKL LRQSPPLPGR EEEPGLGDSG IQSTPGSGHA PRTSSSSDDS KRSPLGKTPL
     GRPAVPRFGK PDGLRGRGVG SPEPGPTAPY LGRSMSYSSQ KAQPGVSETE EVALQPLLTP
     KDEVQLKTTY SKSNGQPKSL GSASPGPGQP PLSSPTRGGV KKVSGVGGTT YEISV
//
